Home Compare AMGN vs GSK.L
Stock Comparison · Industry comparison · Drug Manufacturers - General

Amgen vs GSK: Which Stock Looks Stronger in 2026?

The structural profiles are close, with GSK carrying a narrow edge on stability. The remaining gap is narrow enough that the comparison remains open to different readings. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest score difference appears in stability.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AMGN and GSK.L share the same industry classification.

For a similarity-based comparison, see how Amgen and GSK each position within their functional peer groups in AssetNext.

Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AMGN vs GSK.L Profitability 50 46 Stability 57 69 Valuation 73 80 Growth 75 71 AMGN GSK.L
Gap Ranking
#1 Stability +12
#2 Valuation +7
#3 Growth +4
#4 Profitability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and GSK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNGSK.L Relative valuation Structural strength

The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
Both look solid on stability, though GSK plc still holds the stronger peer position.
Stability — Dominant Gap
AMGN
57
GSK.L
69
Gap+12in favour of GSK.L

The clearest distance comes from a steadier profile over time.

What else supports the lead

GSK plc also shows lower market-fundamental divergence, which makes the lead look less detached from the underlying business picture.

What this means for the comparison

The lead is visible, but it looks newer and less settled than a mature overall lead.

Explore full peer positioning in AssetNext

Break down the AMGN vs GSK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other close comparisons

Explore how AMGN and GSK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.